

Ruth Mokgokong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5400530/publications.pdf>

Version: 2024-02-01

12
papers

118
citations

1684188
5
h-index

1281871
11
g-index

12
all docs

12
docs citations

12
times ranked

205
citing authors

#	ARTICLE	IF	CITATIONS
1	Ion transporters in brain endothelial cells that contribute to formation of brain interstitial fluid. Pflugers Archiv European Journal of Physiology, 2014, 466, 887-901.	2.8	48
2	Nitric Oxide Contributes to Hypoxia-Reoxygenation-Induced P-Glycoprotein Expression in Rat Brain Endothelial Cells. Cellular and Molecular Neurobiology, 2011, 31, 1103-1111.	3.3	17
3	Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithm. Journal of Medical Economics, 2020, 23, 386-393.	2.1	15
4	Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France. Thrombosis and Haemostasis, 2022, 122, 1384-1396.	3.4	13
5	Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom. Health and Quality of Life Outcomes, 2018, 16, 66.	2.4	9
6	Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. Current Medical Research and Opinion, 2021, 37, 891-902.	1.9	5
7	A comparative evaluation of gemtuzumab ozogamicin+Âdaunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia. Future Oncology, 2019, 15, 663-681.	2.4	4
8	Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis. BMJ Open Gastroenterology, 2020, 7, e000456.	2.7	3
9	Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients. Future Oncology, 2021, 17, 2883-2892.	2.4	2
10	Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France. Advances in Therapy, 2022, 39, 3766-3776.	2.9	1
11	Performance of an electronic health record-based predictive model to identify patients with atrial fibrillation across countries. PLoS ONE, 2022, 17, e0269867.	2.5	1
12	Anticoagulant Treatment Patterns and Outcomes in Patients with Venous Thromboembolism and Active Cancer - a Nationwide Cohort Study in France. Blood, 2021, 138, 670-670.	1.4	0